Bronchiolitis obliterans syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the primary factor limiting long-term transplant survival. It is characterized by progressive airflow obstruction resulting in acute rejection of the graft, followed by infections, or other coexistent conditions.
It is generally observed that the median time to diagnose BOS is 16–20 months following lung transplantation. In the majority of patients, BOS is a progressive disease that responds very poorly to the available treatment regimen, i.e., immunosuppressive therapies.
Apart from lung transplantation being the major cause of BOS, several other risk factors can also lead to the development of BOS such as exposure to inhaled toxins and gases, including sulfur mustard gas, nitrogen oxides, diacetyl, fly ash, and fiberglass. It is also known to occur after a respiratory viral infection (adenovirus, respiratory syncytial virus), especially in the case of children.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
The Bronchiolitis Obliterans Syndrome Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Bronchiolitis Obliterans Syndrome market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Bronchiolitis Obliterans Syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Bronchiolitis Obliterans Syndrome Market Key Facts
-
Rachana et al conducted a study titled “Bronchiolitis Obliterans (Obliterative Bronchiolitis, Constrictive Bronchiolitis),” which stated that mostly the long-term survivors are prone to BOS and about 5–14% of HSCT recipients also develop BOS. The disease is also associated with rheumatoid arthritis and graft-versus-host disease, which usually occurs following a lung or hematopoietic cell transplantation.
-
The total prevalent population of Bronchiolitis Obliterans Syndrome (BOS) in the seven major markets was 16,418, in 2017.
-
Delveinsight observed a total of 6,601 prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States in 2017 during the study period, 2017–2030.
- The gender-specific diagnosed prevalent cases of Bronchiolitis Obliterans Syndrome (BOS) in the United States were found to be 3,631 males and 2,971 females, in 2017.
Key Benefits of Bronchiolitis Obliterans Syndrome Market Report
-
Bronchiolitis Obliterans Syndrome market report provides an in-depth analysis of Bronchiolitis Obliterans Syndrome Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Bronchiolitis Obliterans Syndrome Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Bronchiolitis Obliterans Syndrome current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Bronchiolitis Obliterans Syndrome market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Bronchiolitis Obliterans Syndrome Market
The increase in market size is a direct consequence of the increasing prevalent population of Bronchiolitis Obliterans Syndrome (BOS) patients in the 7MM, along with the expected entry of emerging therapies such as Liposomal Cyclosporine A, Ruxolitinib, etc. In addition, favorable initiatives are taken by the federal government also account for the BOS treatment market growth in North American and European regions.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Bronchiolitis Obliterans Syndrome market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Bronchiolitis Obliterans Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Bronchiolitis Obliterans Syndrome Therapeutics Market Assessment
Bronchiolitis Obliterans Syndrome Market Drivers –
-
Extracorporeal Photopheresis—A Promising Prospect
-
Technological Advancements
-
Upcoming Launches and Approval
Bronchiolitis Obliterans Syndrome Epidemiology
The epidemiology section covers insights about the historical and current Bronchiolitis Obliterans Syndrome patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Bronchiolitis Obliterans Syndrome Epidemiology Segmentation –
-
Total Prevalent Population
-
Treatable cases of BOS
-
Gender-Specific Diagnosed Prevalence
-
Grade-Specific Diagnosed Prevalence
-
Total Diagnosed Prevalent Population of BOS in Lung Transplant recipients
-
Total Diagnosed Prevalent Population of BOS in Allogenic Hematopoietic Stem cells (AHSCTs) Transplant recipients
Bronchiolitis Obliterans Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchiolitis Obliterans Syndrome market or expected to get launched in the market during the study period. The analysis covers Bronchiolitis Obliterans Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Bronchiolitis Obliterans Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Bronchiolitis Obliterans Syndrome market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Bronchiolitis Obliterans Syndrome emerging therapies.
Bronchiolitis Obliterans Syndrome Companies:
-
Zambon Pharma
-
Incyte Corporation
-
Genentech
And many others.
Bronchiolitis Obliterans Syndrome therapies covered in the report include:
-
Pirfenidone
-
Ruxolitinib
-
Liposomal Cyclosporine A
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Bronchiolitis Obliterans Syndrome Competitive Intelligence Analysis
4. Bronchiolitis Obliterans Syndrome Market Overview at a Glance
5. Bronchiolitis Obliterans Syndrome Disease Background and Overview
6. Bronchiolitis Obliterans Syndrome Patient Journey
7. Bronchiolitis Obliterans Syndrome Epidemiology and Patient Population
8. Bronchiolitis Obliterans Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Bronchiolitis Obliterans Syndrome Unmet Needs
10. Key Endpoints of Bronchiolitis Obliterans Syndrome Treatment
11. Bronchiolitis Obliterans Syndrome Marketed Products
12. Bronchiolitis Obliterans Syndrome Emerging Therapies
13. Bronchiolitis Obliterans Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Bronchiolitis Obliterans Syndrome Market Outlook (7 major markets)
16. Bronchiolitis Obliterans Syndrome Access and Reimbursement Overview
17. KOL Views on the Bronchiolitis Obliterans Syndrome Market.
18. Bronchiolitis Obliterans Syndrome Market Drivers
19. Bronchiolitis Obliterans Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/bronchiolitis-obliterans-syndrome-market
Latest Reports By DelveInsight
Bronchiolitis Obliterans Syndrome Pipeline Insights
Bronchiolitis Obliterans Syndrome Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Bronchiolitis Obliterans Syndrome market.
Acute Respiratory Distress Syndrome (ARDS) Market
DelveInsight’ s “Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market size, share, trends, growth and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market